BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

FDA Approves Dako A/S's HercepTest(TM) and HER2 FISH pharmDx(TM) Kit as Companion Diagnostics for Genentech (RHHBY)'s New Cancer Drug Perjeta(TM)


6/12/2012 8:08:26 AM

GLOSTRUP, DENMARK--(Marketwire - June 11, 2012) - Dako, a world leading provider of cancer diagnostics solutions, has received approval from the US Food and Drug Administration to market HercepTest™ and HER2 FISH pharmDx™ Kit as companion diagnostics for pertuzumab (Perjeta™) - a new Genentech cancer drug.

Today's announcement is the result of the collaboration between Genentech and Dako on a parallel US FDA approval process of Genentech's cancer drug and Dako's pharmDx™ assays.

The Genentech cancer drug (pertuzumab) - which has also received authorization from FDA - will be marketed under the name Perjeta™.

"The role of HER2 in diagnosis and clinical decision making continues to evolve with the recent approval of Perjeta, a new targeted biologic therapy for patients with advanced HER2-positive breast cancer. It is clear that optimal patient care depends now more than ever on the accurate, reliable, and reproducible assessment of the HER2 status for the full benefit of Perjeta to be derived by the appropriate patient population," says David Hicks, M.D., Director of Surgical Pathology, University of Rochester Medical Center, New York.

Dako's HercepTest™ and HER2 FISH pharmDx™ Kit will serve as diagnostic tools to identify cancer patients with HER2-positive metastatic breast cancer who may be eligible for Perjeta™ treatment.

"Certainty goes to the very heart of Dako. We are therefore extremely pleased to make our high quality pharmDx products for Perjeta available to our US customers. Dako supports laboratories and doctors in the process of identifying HER2-positive breast cancer and this way we make vital treatment available to patients battling this aggressive disease," says Lars Holmkvist, CEO of Dako.

The FDA approval announced today is in line with Dako's ongoing strategy to combine strengths with international pharmaceutical companies to grow the offering of Dako's pharmDx™ assays.

Dako's HercepTest™ and HER2 FISH pharmDx™ Kit as companion diagnostics for Perjeta™ will be available to customers in the United States as of today.

About pharmDx™ pharmDx™(pharmacoDiagnostic®) is Dako's trade name for a group of products which are used to select patients for a particular pharmaceutical treatment (companion diagnostics) or to monitor how well a specific treatment is working.

About Dako

Dako, based in Denmark, is a global leader in tissue-based cancer diagnostics. Hospital and research laboratories worldwide use Dako's know-how, reagents, instruments and software to make precise diagnoses and determine the most effective treatment for patients suffering from cancer. Employing more than 1,000 people and operating in more than 100 countries, Dako covers essentially all of the global anatomic pathology markets. On May 16, 2012, Agilent Technologies, Inc. entered into an agreement with EQT - a Swedish-based private equity group - to acquire Dako. The acquisition is expected to be completed within 60 days of signing. For more information please visit www.dako.com

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Dako Denmark A/S via Thomson Reuters ONE

[HUG#1618928]


Media Contact
Maia Fredtoft Sochting
Corporate Communications
Dako Denmark A/S
Tel. +45 25 46 10 83



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES